This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human C-Reactive Protein (CRP) Protein, His Tag
catalog :
CRP-H5226
quantity :
250 ug, 1 mg
price :
150 USD, 470 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CRP-H5226
product name :
Human C-Reactive Protein (CRP) Protein, His Tag
quantity :
250 ug, 1 mg
price :
150 USD, 470 USD
quantity & price :
$150/250ug,$470/1mg (250ug × 4)
target :
C-Reactive Protein
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human C-Reactive Protein, His Tag (CRP-H5226) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Pro 224 (Accession # NP_000558.2).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human C-Reactive Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Supplied as 0.2 μm filtered solution in Tris-NaCl buffer pH8.0 with trehalose as protectant. Contact us for customized product form or formulation.
Storage :
Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● The product MUST be stored at -70°C or lower upon receipt;
● -70℃ for 3 months under sterile conditions.
Background :
C-reactive protein (CRP) is a member of the pentraxin family of proteins that are characterized by a cyclic pentameric structure. Human CRP gene encodes a 224 amino acids precursor. The mature human CRP protein has 206 amino acids that are noncovalently linked to form the pentameter. Human CRP shares 71% and 64% amino acid sequence homology with mouse and rat respectively. CRP, synthesized by hepatocytes, is a major acute phase serum protein in human. IL6, IL1 and glucocorticoids are the major inducer of the CRP gene. The physiological role of CRP is to bind to phosphocholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system. CRP binds to phosphocholine on microbes and damaged cells and enhances phagocytosis by macrophages. Thus, CRP participates in the clearance of necrotic and apoptotic cells. CRP rises up to 50,000-fold in acute inflammation, such as infection. It rises above normal limits within 6 hours, and peaks at 48 hours. Its half-life is constant, and therefore its level is mainly determined by the rate of production. It has been shown that high levels of CRP in humans is associated with an increased risk of cardiovascular diseases.
References :
(1) Pepys MB, Hirschfield GM. 2003, J Clin Invest 111 (12): 1805–12.
(2) Lau DC., 2005, Am J Physiol Heart Circ Physiol 288 (5): H2031–41.
company information

ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments
